Nab-paclitaxel plus tegafur gimeracil oteracil potassium capsule (S-1) as first-line treatment for advanced biliary tract adenocarcinoma: a phase 2 clinical trial.

ABSTRACT:

Background

This study aimed to evaluate the efficacy and safety of a new combination of nab-paclitaxel plus tegafur gimeracil oteracil potassium capsule (S-1) for patients with advanced biliary tract carcinoma (BTC).

Methods

Patients were treated with nab-paclitaxel at a dose of 125 mg/m² on day 1 and 8, and S-1, 80 to 120 mg/day on days 1-14 of a 21-day cycle. Treatments were repeated until disease progression or unacceptable toxicity occurred. The primary endpoint was objective response rate (ORR). The secondary endpoints were median progression-free survival (PFS), overall survival (OS), and adverse events (AEs).

Results

The number of patients enrolled were 54, and 51 patients were evaluated for efficacy. A total of 14 patients achieved partial response

SUBMITTER: Zhang W 

PROVIDER: S-EPMC9944545 | biostudies-literature | 2023 Feb

REPOSITORIES: biostudies-literature